Efficacy, tolerability, and safety of rapid initiation of topiramate versus phenytoin in patients with new-onset epilepsy: a randomized double-blind clinical trial

Epilepsia
Eugene RamsayCAPSS-272 Study Group

Abstract

To evaluate topiramate (TPM) and phenytoin (PHT) monotherapy following rapid oral initiation in new-onset epilepsy. Randomized, double-blind, 28-day trial of TPM (100 mg/day beginning on day 1) versus PHT (1,000 mg on day 1 followed by 300 mg/day maintenance dosing) in 261 patients with new-onset epilepsy. The primary end point was time to seizure, and the primary objective was to establish noninferiority of TPM to PHT in the risk of seizure. At day 28, the estimated seizure-free rate was 81.1% for TPM treatment in comparison with 90.3% for PHT treatment. Noninferiority of TPM to PHT (primary objective) could not be established [hazard ratio (HR) 2.0, 95% confidence interval (CI), 0.98 to 4.12, p = 0.366), and PHT could not be shown to be superior to TPM. A higher percentage discontinued with PHT compared to TPM for all reasons (21.1 vs. 12.8%) and due to adverse events (13.4 vs. 6.8%). The most common treatment-related adverse events in both groups were dizziness, paresthesia, and somnolence. A post hoc analysis showed that TPM was superior to PHT in time to discontinuation (retention rate) for all causes (89.4% vs. 80.3%, p = 0.047). This study was inconclusive in establishing noninferiority of TPM 100 mg/day compared to a st...Continue Reading

References

Nov 14, 1992·BMJ : British Medical Journal·J K AronsonD J Reynolds
Aug 23, 1990·The New England Journal of Medicine·N R TemkinH R Winn
Apr 1, 1987·Annals of Emergency Medicine·H H OsbornR Sparano
Sep 1, 1973·Clinical Pharmacology and Therapeutics·B J WilderR E Ramsay
Feb 6, 1970·Biochemical and Biophysical Research Communications·T ChangA J Glazko
Sep 26, 1980·JAMA : the Journal of the American Medical Association·J C CloydL W McLain
Feb 12, 1998·The New England Journal of Medicine·W A HauserV E Anderson
May 30, 1998·The American Journal of Cardiology·M W RussellS C Hartz
Oct 26, 1999·The Annals of Pharmacotherapy·I C WongJ W Sander
Feb 7, 2001·Arquivos de neuro-psiquiatria·P C Trevisol-BittencourtA R Troiano
Feb 24, 2001·The Annals of Pharmacotherapy·V BitonUNKNOWN Topiramate TPS-TR Study Group
Mar 29, 2001·Neurology·R S FisherP Bernstein
Jun 5, 2001·Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine·J S HuffUNKNOWN Emergency Medicine Seizure Study Group
May 22, 2002·Therapeutic Drug Monitoring·Hoan Linh BanhMichael R Sperling
Mar 5, 2003·Acta Neurologica Scandinavica·M D PriviteraUNKNOWN EPMN 105 Study Group
Sep 9, 2005·Acta Neurologica Scandinavica·S ArroyoUNKNOWN EPMN-106/INT-28 Investigators
Jul 10, 2007·Seizure : the Journal of the British Epilepsy Association·H P R BootsmaA P Aldenkamp
Jul 21, 2007·Journal of Child Neurology·Tracy A GlauserUNKNOWN EPMN-106/INT-28 Investigators
Jul 24, 2007·Annals of Emergency Medicine·Thomas B PurcellRobert Chavez
Feb 22, 2008·Epilepsia·Anne T Berg
Jan 29, 2008·Mini Reviews in Medicinal Chemistry·Giuseppe LatiniFrancesco Chiarelli
May 30, 2008·Neurology·M Z KoubeissiM A Werz

❮ Previous
Next ❯

Citations

May 22, 2013·Seminars in Fetal & Neonatal Medicine·Ronit M Pressler, B Mangum
May 27, 2014·Expert Opinion on Pharmacotherapy·Anand Iyer, Anthony Marson
May 7, 2014·Expert Opinion on Pharmacotherapy·Sylvain Rheims, Philippe Ryvlin
Feb 26, 2016·CNS Drugs·David S Gloss, Allan Krumholz
Sep 25, 2015·CNS Drugs·Anna RosatiRenzo Guerrini
Nov 27, 2014·Journal of Clinical Psychopharmacology·Clifford M KnappCourtney Richambault
Jul 19, 2016·Clinical Neuropharmacology·Rachel G GreenbergJeffrey T Guptill
Oct 26, 2016·Pharmacotherapy·Marília Silveira de Almeida CamposLeonardo Régis Leira Pereira
May 10, 2017·Expert Opinion on Pharmacotherapy·Giangennaro CoppolaAlberto Verrotti
Dec 1, 2012·Therapeutic Advances in Drug Safety·Marco Mula
Jul 1, 2017·The Cochrane Database of Systematic Reviews·Sarah J NevittAnthony G Marson
Dec 16, 2017·The Cochrane Database of Systematic Reviews·Sarah J NevittAnthony G Marson
Nov 14, 2016·Epilepsia Open·Amerins WeijenbergUNKNOWN LEV‐VPA Study Group
Jul 24, 2021·Neuropsychopharmacology Reports·Tahir Hakami
Oct 8, 2021·Seminars in Neurology·Myriam AbdennadherMilena K Pavlova

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.